Metabolism of phencyclidine by human liver microsomes

Drug Metabolism and Disposition

Volumn 25, Issue 5, 1997, Pages 557-563

  Laurenzana, Elizabeth M ^b   Owens, S Michael ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; PHENCYCLIDINE; TESTOSTERONE; TROLEANDOMYCIN;

ARTICLE; DRUG ACTIVITY; DRUG DISPOSITION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HALLUCINOGENS; HUMANS; HYDROXYLATION; INFANT; ISOENZYMES; MALE; MICROSOMES, LIVER; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PHENCYCLIDINE; TESTOSTERONE; TROLEANDOMYCIN;

EID: 0030984837     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. F. E. Greifenstein, J. Yoshitake, M. DeVault, and J. E. Gajewski: A study of 1-aryl cyclohexylamine for anesthesia. Anesth. Analg. 37, 283-294 (1958).
2. P. V. Luisada: The phencyclidine psychosis: phenomenology and treatment. In "NIDA Research Monograph 21 Phencyclidine Abuse: an appraisal" (R. C. Peterson and R. C. Stillman, eds.), pp.241-253, U.S. Govt. Printing Office, Washington, D.C., 1978.
3. B. Fauman, G. Aldinger, M. Fauman, and P. Rosen: Psychiatric sequelae of phencyclidine abuse. Clin Toxicol. 9, 529-538 (1976).
4. R. Quirion, M. A. Bayorah, R. L. Zerbe, and C. B. Pert: Chronic phencyclidine decreases phencyclidine and dopamine receptors in rat brain. Pharmacol. Biochem. Behav. 17, 699-702 (1982).
5. H. H. Fundenburg, H. D. Whitten, E. Merler, and O. Farmati: Is schizophrenia an immunological receptor disorder? Med. Hypoth. 12, 85-93 (1983).
6. N. Khansari, H. D. Whitten, and H. H. Fundenburg: Phencyclidine-induced immunosupression. Science 225, 76-78 (1984).
7. F. C. P. Law: Metabolic disposition and irreversible binding of phencyclidine in rats. Toxicol. Applied Pharmacol. 57, 263-272 (1981).
8. M. K. P. Hoag, A. J. Trevor, A. Kalir, and N. Castagnoli, Jr.: Phencyclidine iminium ion: NADPH-dependent metabolism, covalent binding to macromolecules, and inactivation of cytochrome(s) P-450. Drug Metab. Dispos. 15, 485-490 (1987).
9. C. E. Cook, D. R. Brine, A. R. Jeffcoat, J. M. Hill, M. E. Wall, M. Perez-Reyes, and S. R. Di Guiseppi: Phencyclidine disposition after intravenous and oral doses. Clin. Pharmacol. Ther. 31, 625-634 (1982).
10. C. E. Cook, D. R. Brine, G. D. Quin, M. Perez-Reyes, and S. R. Di Guiseppi: Phencyclidine and phenylcyclohexene disposition after smoking phencyclidine. Clin. Pharmacol. Ther. 31, 635-641 (1982).
11. C. E. Cook, A. R. Jeffcoat, and M. Perez-Reyes: Pharmacokinetic studies of cocaine and phencyclidine in man. In "Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs" (G. Barnett and C. N. Chiang, eds.), pp. 48-74. Biomedical Publications, Forest City, CA, 1985.
12. L. M. Forrester, C. J. Henderson, M. J. Glancey, D. J. Back, B. K. Park, S. E. Ball, N. R. Kitteringham, A. W. McLaren, J. S. Miles, P. Skett, and C. R. Wolf: Relative expression of cytochrome P450 isozymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem. J. 281, 359-368 (1992).
13. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengreich: Interindividual variations in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
14. K. Brosen: Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin. Pharmacokinet. 18, 220-239 (1990).
15. F. P. Guengerich and T. Shimada: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4, 391-407 (1991).
16. E. J. Holsztynska and E. F. Domino: Biotransformation of phencyclidine. Drug Metab. Rev. 16, 285-320 (1986).
17. R. C. Kammerer and A. K. Cho: The biotransformation of phencyclidine. In "PCP (Phencyclidine): Historical and Current Perspectives" (E. F. Domino, ed.), pp. 177-189. NPP Books, Ann Arbor, MI, 1981.
18. E. J. Holsztynska and E. F. Domino: Biotransformation is a major mechanism for terminating the action of phencyclidine (PCP) in mice. Pharmacologist 23, 192 (1981).
19. M. Mayersohn, S. M. Owens, and J. R. Woodworth: Phencyclidine disposition in animals. In "Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs" (G. Barnett and C. N. Chiang, eds.), pp. 28-47. Biomedical Publications, Forest City, CA, 1985.
20. T. Aoyama, F. J. Gonzalez, and H. V. Gelboin: Human cDNA expressed cytochrome P450 IA2: mutagen activation and substrate specificity. Mol. Carcinogen. 2, 192-198 (1989).
21. M. A. Butler, M. Iwaski, F. P. Guengerich, and F. F. Kadlubar: Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA 86, 7696-7700 (1989).
22. J. S. Miles, A. W. McLaren, L. M. Forrester, M. J. Glancey, M. A. Lang, and C. R. Wolf: Identification of the human liver cytochrome P-450 responsible for 7-hydroxylase activity. Biochem. J. 267, 365-371 (1990).
23. M. V. Relling, T. Aoyama, F. J. Gonzalez, and U. A. Meyer: Tolbutamide and mephenytion hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252, 442-447 (1990).
24. 1 activity. Clin. Pharmacol. Ther. 45, 34-40 (1989).
25. V. Carriere, T. Goasduff, D. Ratanasavanh, F. Morel, J. C. Gautier, A. Guillouzo, P. Beaune, and F. Berthou: Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem. Res. Toxicol. 6, 852-857 (1993).
26. D. J. Waxman, C. Attisano, F. P. Guengerich, and D. P. Lapenson: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263, 424-436 (1988).
27. P. J. Castle, J. L. Merdink, J. R. Okita, S. A. Wrighton, and R. T. Okita: Human liver lauric acid hydroxylase activities. Drug Metab. Dispos. 23, 1037-1043 (1995).
28. C. B. Walberg, M. M. McCarron, and B. W. Schulze: Quantitation of phencyclidine in serum by enzyme immunoassay: results in 405 patients. J. Anal. Toxicol. 7, 106-110 (1983).
29. J. L. Valentine and S. M. Owens: Anti-phencyclidine monoclonal antibodies significantly changes phencyclidine concentrations in brain and other tissues in rats. J. Pharmacol. Exp. Ther. 278, 717-724 (1996).
30. S. M. Owens, M. Gunnell, E. M. Laurenzana, and J. L. Valentine: Dose-and time-dependent changes in phencyclidine metabolite covalent binding in rats and the possible role of CYP2D1. J. Pharmacol. Exp. Ther. 265, 1262-1266 (1993).
31. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic gents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
32. S. R., Shelnutt, T. M. Badger, and S. M. Owens: Phencyclidine metabolite irreversible binding in the rat: gonadal steroid regulation and CYP2C11. J. Pharmacol. Exp. Ther. 277, 292-298 (1996).
33. T. K. H. Chang, F. J. Gonzalez, and D. J. Waxman: Evaluation of triacetyloleandomycin, α-napthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311, 437-442 (1994).
34. D. J. Waxman, C. Attisano, F. P. Guengerich, and D. P. Lapenson: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263, 424-436 (1988).
35. B. Gemzik, D. Greenway, C. Nevis, and A. Parkinson: Regulation of two electrophoretically distinct proteins recognized by an antibody against rat liver cytochrome 450 3A1. J. Biochem. Toxicol. 7, 43-52 (1992).
36. D. Eberhart, K. Fitzgerald, and A. Parkinson: Evidence for the involvement of a distinct form of cytochrome P450 3A in the oxidation of digitoxin by rat liver microsomes. J. Biochem. Toxicol. 7, 53-64 (1992).
37. M. Kitada, T. Kamataki, K. Itahashi, T. Rikihisa, and Y. Kanakubo: Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations. Proc. Natl. Acad. Sci. USA 86, 462-465 (1989).
38. R. T. Coutts, P. Su, and G. B. Baker: Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 enzymes in N-dealkylation reactions. J. Pharmacol. Toxicol. Meth. 31, 177-186 (1994).
39. D. R. Nelson, L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, and D. W. Nebert: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42 (1996).
40. S. A. Wrighton, B. J. Ring, P. B. Watkins, and M. Vandenbranden: Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 36, 97-105 (1989).
41. S. A. Wrighton, W. R. Brian, M.-A. Sari, M. Iwasaki, F. P. Guengerich, J. L. Raucy, D. T. Molowa, and M. Vandenbranden: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207-213 (1990).
42. J. R. Halpert: Multiplicity of steroid-inducible cytochromes P-450 in rat liver microsomes. Arch. Biochem. Biophys. 263, 59-68 (1988).
43. F. F. Kadlubar, M. A. Butler, K. R. Kaderlik, H. C. Chou, and N. P. Lang: Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Env. Health Perspect. 98, 69-74 (1992).
44. D. J. Gole, J.-L. Pirat, J.-M. Kamenka, and E. F. Domino: Hydroxy metabolites of phencyclidine: identification and quantitation of two novel metabolites. Drug Metab. Dispos. 16, 386-391 (1988).
45. R. Pohorecki, W. Rayburn, W. W. Coon, and E. F. Domino: Some factors affecting phencyclidine biotransformation by human liver and placenta. Drug Metab. Dispos. 17, 271-274 (1989).
46. M. A. Zorbas and S. M. Owens: Development of an animal model for studying the pharmacological consequences of in vivo PCP metabolite covalent binding. In "Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection?" (J.-M. Kamenka and E. F. Domino, eds.), pp. 817-830. NPP Books, Ann Arbor, MI, 1992.
47. J. R. Crowley and P. F. Hollenberg: Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion. Drug Metab. Dispos. 23, 786-793 (1995).
48. Y. Osawa and M. J. Coon: Selective mechanism-based inactivation of the major phenobarbital-inducible P-450 cytochrome from rabbit liver by phencyclidine and its oxidation product, the iminium compound. Drug Metab. Dispos. 17, 7-13 (1989).
49. F. C. P. Law and T. E. Farquharson: Metabolism and irreversible binding of phencyclidine by rabbit lung and liver microsomes. In "Microsomes, Drug Oxidations, and Chemical Carcinogenesis" (M. J. Coon, A. H. Conney, R. W. Estabrook, H. V. Gelboin, J. R. Gillette, and P. J. O'Brien, eds.), pp. 985-988. Academic Press, New York, 1980.
50. M. K. P. Hoag, A. J. Trevor, Y. Asscher, J. Weissman, and N. Castagnoli, Jr.: Metabolism-dependent inactivation of liver microsomal enzymes by phencyclidine. Drug Metab. Dispos. 12, 371-375 (1984).
51. F. M. Farin and C. J. Omiecinski: Regiospecific expression of cytochrome P-450s and microsomal expoxide hydrolase in human brain tissue. J. Toxicol. Environ. Health 40, 317-335 (1993).